CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.
Right arrow Articles by Igarashi, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.
Right arrow Articles by Igarashi, I.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, May 2006, p. 553-555, Vol. 13, No. 5
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.5.553-555.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Immunochromatographic Test for Simultaneous Serodiagnosis of Babesia caballi and B. equi Infections in Horses

Xiaohong Huang,1,2 Xuenan Xuan,1 Rodolfo A. Verdida,1 Shoufa Zhang,3 Naoaki Yokoyama,1 Longshan Xu,2 and Ikuo Igarashi1*

National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan,1 Fujian Provincial Center for Diseases Control and Prevention, Fuzhou, Fujian Province 350001, China,2 Department of Veterinary Medicine, Yanbian University, Longjing, Jilin Province 133400, China3

Received 6 December 2005/ Returned for modification 30 January 2006/ Accepted 6 March 2006


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
An immunochromatographic test for the simultaneous detection of Babesia caballi- and B. equi-specific antibodies (BceICT) was developed using a recombinant B. caballi 48-kDa rhoptry protein (rBc48) and a recombinant truncated B. equi merozoite antigen 2 (rEMA-2t). An evaluation of the ability of the BceICT to detect antibodies in sera from uninfected horses and experimentally infected horses showed high sensitivities and specificities of 83.3% (10/12 sera) and 92.9% (52/56 sera), respectively, for the anti-B. caballi antibody and 94.1% (16/17 sera) and 88.2% (45/51 sera), respectively, for the anti-B. equi antibody. Results from the detection of antibodies in field-collected sera indicated that the BceICT results corresponded with those of enzyme-linked immunosorbent assays (ELISA), showing 91.8% correspondence (67/73 sera) for B. caballi and 95.9% correspondence (70/73 sera) for B. equi, and that the BceICT results also corresponded with the ICT for B. caballi and for B. equi, both of which were 98.2% (55/56 sera). The comparable results of the ICT and ELISA and the simplicity and rapidity of the performance of the ICT suggest that the BceICT would be a feasible test for the simultaneous serodiagnosis of both agents of equine babesiosis in the field.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Equine piroplasmosis, caused by Babesia caballi and Babesia equi, is an important protozoan disease worldwide from both veterinary and economic viewpoints (2). Various serodiagnostic tests have been developed for the disease, such as the complement fixation test (1, 11, 12), the indirect immunofluorescent antibody test (1, 11, 12), the enzyme-linked immunosorbent assay (ELISA) (1, 3, 5, 7, 8, 9, 10, 13, 14), the competitive-inhibition ELISA (9), and the immunochromatographic test (ICT) (6). In our previous studies, ELISAs for the serodiagnoses of B. caballi and B. equi infections demonstrated many advantages, such as higher sensitivity and specificity, lower cost of materials, and greater objectivity in the determination of results (5, 8), over the complement fixation test, indirect immunofluorescent antibody test, and competitive-inhibition ELISA. Compared with ELISA, however, the ICT is relatively simple, can be performed quickly, and has the listed advantages of ELISA (6).

Babesia caballi and B. equi have overlapping geographical distributions (4). In such areas, an individual horse may be infected by both species. Therefore, a test capable of detecting the antibodies induced by both types of parasites would be desirable. Here, we report an ICT for the simultaneous detection of B. caballi- and B. equi-specific antibodies (BceICT) that uses the recombinant B. caballi 48-kDa rhoptry protein (rBc48) and the recombinant truncated B. equi merozoite antigen 2 (rEMA-2t) as antigens for the simultaneous serodiagnosis of infections caused by two Babesia spp. in horses.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
rEMA-2t. rEMA-2 was expressed in Escherichia coli as a fusion protein with glutathione S-transferase, as described previously (5). The fusion protein was purified using glutathione Sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden). The leader protein, glutathione S-transferase, was cleaved by thrombin protease.

rBc48. rBc48 was prepared as described previously, with some modification (7, 8). Briefly, the Bc48 gene inserted into pBluescript SK(+) vectors was subcloned into pGEX-4T (Amersham) of the bacterial expression vector after digestion with EcoRI and XhoI. The E. coli (BL21 strain) colony transformed with pGEX-4T/Bc48 was cultured on a small scale overnight in Luria-Bertani (LB) medium (1% Bacto tryptone, 0.5% yeast extract, 1% NaCl, and 0.1% 5 N NaOH) with 50 µg/ml of ampicillin sodium at 37°C. The overnight culture was then diluted to 1:100 in an LB medium for a large-scale culture at 25°C. When the optical density at 600 nm (OD600) reached 0.50, E. coli was induced to express the rBc48 protein by the addition of 0.5 mM isopropyl-ß-D-thiogalactopyranoside and incubation for another 4 h at 25°C. The purification procedure for rBc48 was the same as that for rEMA-2t.

Conjugates. After dialysis in a 5 mM phosphate buffer at the proper pH (6.5 for rEMA-2t and 8.0 for rBc48), rEMA-2t and rBc48 were diluted to their optimal concentrations, 200 µg/ml and 125 µg/ml, respectively, and mixed gently with gold colloid particles (British BioCell International, SDX, United Kingdom) at the optimal pH. The ratio of volumes was 1:10. The mixtures were incubated at room temperature for 10 min without disturbance. Then, 0.05% polyethylene glycol 20,000 (PEG) and 1% bovine serum albumin (BSA) were added to stabilize and block the conjugate particles. After centrifugation at 18,000 x g for 20 min, 90% of the supernatants were discarded, and the pellets were resuspended in the remaining supernatants by sonication and then washed with phosphate-buffered saline containing 0.5% BSA and 0.05% PEG. Following the second centrifugation, the pellets were resuspended in phosphate-buffered saline with 0.5% BSA and 0.05% PEG until the OD520 reached 5. After the two conjugates were mixed and diluted in 10 mM Tris-HCl (pH 8.2) with 5% sucrose, the mixture was sprayed onto glass fiber (Schleicher & Schuell, NH) and dried in a vacuum overnight.

Rabbit anti-rEMA-2t IgG. A rabbit was immunized with 1 ml of rEMA-2t (2 mg/ml) mixed with 1 ml of complete Freund's adjuvant (Difco, Detroit, MI) by multiple intradermal injections into its dorsum. Two booster injections were given in a 2-week interval, with the same dose of antigen mixed with incomplete Freund's adjuvant (Difco). The rabbit was bled 10 days after the last booster. The immunoglobulin G (IgG) fraction was purified from blood serum with an Econo-Pac protein A kit (Bio-Rad, CA) according to the manufacturer's instructions and used as the control for the ICT.

Immobilization of rEMA-2t, rBc48, and rabbit anti-rEMA-2t IgG on nitrocellulose (NC) membrane. rEMA-2t (500 µg/ml), rBc48 (125 µg/ml), and rabbit anti-rEMA-2t IgG (1,500 µg/ml) were linearly jetted onto an NC membrane with a plastic backing (Schleicher & Schuell, NH) using a BioDot Biojet 3050 quanti-dispenser (BioDot, Inc., CA). The positions of the three lines are shown in Fig. 1. The membrane was dried at 50°C for 30 min and blocked with 0.5% casein in a 50 mM boric acid buffer (pH 8.5) for 30 min. After a wash with 50 mM Tris-HCl (pH 7.4) containing 0.5% sucrose and 0.05% sodium cholate, the membrane was air dried overnight.


Figure 1
View larger version (52K):
[in this window]
[in a new window]
  		FIG. 1. Pretest (lane 1) and posttests (lanes 2 to 5) of BceICT strips. Bc test line: rBc48 was immobilized on the nitrocellulose membrane for the detection of antibody to B. caballi. Be test line: rEMA-2t was immobilized on the nitrocellulose membrane for the detection of antibody to B. equi. Lanes: 1, pretest; 2, antibodies to both B. caballi and B. equi are positive; 3, only the antibody to B. caballi is positive; 4, only the antibody to B. equi is positive; 5, the antibodies to both B. caballi and B. equi are negative.

 
Assemblage of test strips and detection of specific antibodies in horse serum. The NC membrane containing antigens and antibodies was assembled on an adhesive card (Schleicher & Schuell) with other components, such as an absorbent pad, a conjugate pad, and a sample pad, and cut into 6-mm-wide strips using a BioDot cutter (BioDot, Inc.), as shown in Fig. 1 (lane 1). Detection was performed by pipetting 100 µl of serum onto the sample pad. In the preliminary test, color in the control line took a maximum of 7 min to develop; color in the test lanes took a maximum of 15 min to develop, and the results did not change when the sample pad was read later than 15 min. Therefore, results were determined 15 min after the application of serum samples and recorded as (i) positive for both equine babesiosis species (Fig. 1, lane 2); (ii) positive for B. caballi and negative for B. equi (Fig. 1, lane 3); (iii) negative for B. caballi and positive for B. equi (Fig. 1, lane 4); and (iv) negative for both B. caballi and B. equi (Fig. 1, lane 5).

Sera. Thirty-nine uninfected sera were from race horses in Japan, a country assumed to be free of equine babesiosis. Twelve B. caballi- and 17 B. equi-infected sera were from horses infected experimentally with the parasites. Of the 73 field-collected sera, 56 were from horses in Jilin province, China, and 17 were from horses imported to Japan from different countries suspected of harboring Babesia infections.


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Detection of specific antibodies against B. caballi and B. equi in sera from experimentally infected horses. The results of experiments for the detection of specific antibodies are summarized in Tables 1 and 2. The sensitivities and specificities of the BceICT were 83.3% (10/12 sera) and 92.9% (52/56 sera), respectively, for the detection of the antibody against B. caballi and 94.1% (16/17 sera) and 88.2% (45/51 sera), respectively, for the detection of the antibody against B. equi infection. The sensitivity of the BceICT for detecting antibodies to B. caballi (83.3%) and B. equi (94.1%) were equal to those of B. caballi ELISA (BcELISA) and B. equi ELISA (BeELISA). On the other hand, the specificity of the BceICT for detecting antibodies to B. caballi (92.9%) and B. equi (88.2%) were slightly lower than those of BcELISA (100%) and BeELISA (100%).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Comparison of BceICT with BcELISA in the detection of specific antibodies against B. caballi in equine seraa

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Comparison of BceICT with BeELISA in the detection of specific antibodies against B. equi in equine seraa

 
Detection of specific antibodies against B. caballi and B. equi in sera from horses in an area of endemicity. Comparisons between the BceICT and ELISAs in the detection of field-collected sera are shown in the last columns of Tables 1 and 2. The comparisons between the BceICT and BcICT and between the BceICT and BeICT are summarized in Table 3. The corresponding results were 91.8% (67/73) between BceICT and BcELISA, 95.9% (70/73) between BceICT and BeELISA, 98.2% (55/56) between BceICT and BcICT, and 98.2% (55/56) between BceICT and BeICT.


View this table:
[in this window]
[in a new window]
  		TABLE 3. Comparison of BceICT with BcICT and BeICT in the detection of specific antibodies against B. caballi and B. equi infections in field sera

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The ICT is a nitrocellulose membrane-based immunoassay that relies on the migration of a liquid across the surface of the membrane by the capillary mechanism and the capture of the antibodies in the sample using the antigens in the mobile phase, which are conjugated with gold particles, and antigens and antibodies in the immobile phase. The captured antigen and antibody complex then develops a colored line. As soon as the test strip is available, the performance is as simple as loading the sample onto the strip, and the result can be determined in a few minutes with the naked eye, according to the colored lines. No equipment or testing skills are required. Therefore, this test is more practical to use in the field than any other test. In our previous studies, the BcICT and BeICT were developed for the detection of antibodies to B. caballi (unpublished data) and B. equi (6). Both of the tests showed results that were comparable with those of ELISAs. To combine the two ICTs into one test, we developed a BceICT for the simultaneous detection of antibodies against infection by two species of Babesia. Using this test, some materials used for the preparation of test strips, sera, manpower, and time required could be reduced by one-half.

Detection results of the specific antibodies in the known B. caballi- and B. equi-infected and uninfected horses indicate that the sensitivity and specificity of the BceICT was 83.3% and 92.9%, respectively, for anti-B. caballi antibody and 94.1% and 88.2%, respectively, for anti-B. equi antibody. No significant differences were observed in sensitivity between BceICT and BcELISA and between BceICT and BeELISA. However, the specificity of the BceICT was less than those of BcELISA and BeELISA. The nonspecific reaction in the BceICT for the detection of B. equi infection was observed mainly in sera from B. caballi-infected horses, in reverse, and that for the detection of B. caballi infection was observed mainly in sera from B. equi-infected horses. Therefore, these nonspecific reactions may be due to an antigen or antibody cross-reaction rather than the effect of some physical or chemical factors. The reaction may occur when the two conjugates are mixed. Other possibilities are related to the storage of the sera, for example, the length of the storage period, the quantity of preservative added, or the conditions for the preparation of the test strips. If further discrimination between the two species is necessary, ELISAs could be carried out to examine the BceICT-positive sera.

The high correspondence of BceICT results with ICT or ELISA results were also found for B. caballi and B. equi infections, respectively, in sera collected from horses in the field. The correspondence of the BceICT with BcELISA, BeELISA, BcICT, and BeICT were 91.8%, 95.9%, 98.2%, and 98.2%, respectively (Tables 1, 2, and 3). These results for B. equi infection were very comparable with those in previous studies (6).

In conclusion, the present study indicates that the BceICT employing antigen bound to nitrocellulose membranes has a high specificity and sensitivity for detecting antibodies to both B. caballi and B. equi. The results of the BceICT are easily obtained and comparable with those from ELISA. Therefore, the BceICT is a feasible field test for the simultaneous serodiagnosis of both types of equine babesiosis, even though some improvements of the BceICT and an evaluation on a larger scale are necessary.


   ACKNOWLEDGMENTS
 
This study was supported by grants from the 21st Century COE Program (A-1) and Ministry of Education, Culture, Sports, Science, and Technology, Japan, and by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.


   FOOTNOTES
 
* Corresponding author. Mailing address: National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan. Phone: 81-155-49-5641. Fax: 81-155-49-5643. E-mail: igarcpmi{at}obihiro.ac.jp. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Bruning, A. 1996. Equine piroplasmosis: an update on diagnosis, treatment, and prevention. Br. Vet. J. 152:139-151.[Medline]
  2. de Waal, D. T. 2000. Global importance of piroplasmosis. J. Protozool. Res. 10:106-127.
  3. Hirata, H., H. Ikadai, N. Yokoyama, X. Xuan, K. Fujisaki, N. Suzuki, T. Mikami, and I. Igarashi. 2002. Cloning of a truncated Babesia equi gene encoding an 82-kilodalton protein and its potential use in an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 40:1470-1474.[Abstract/Free Full Text]
  4. Holbrook, A. A. 1969. Biology of equine piroplasmosis. J. Am. Vet. Med. Assoc. 155:453-454.[Medline]
  5. Huang, X., X. Xuan, N. Yokoyama, L. Xu, H. Suzuki, C. Sugimoto, H. Nagasawa, K. Fujisaki, and I. Igarashi. 2003. High-level expression and purification of a truncated merozoite antigen-2 of Babesia equi in Escherichia coli and its potential for immunodiagnosis. J. Clin. Microbiol. 41:1147-1151.[Abstract/Free Full Text]
  6. Huang, X., X. Xuan, L. Xu, S. Zhang, N. Yokoyama, N. Suzuki, and I. Igarashi. 2004. Development of an immunochromatographic test with recombinant EMA-2 for the rapid detection of antibodies against Babesia equi in horses. J. Clin. Microbiol. 42:359-361.[Abstract/Free Full Text]
  7. Ikadai, H., X. Xuan, I. Igarashi, S. Tanaka, T. Kanemaru, H. Nagasawa, K. Fujisaki, N. Suzuki, and T. Mikami. 1999. Cloning and expression of a 48-kilodalton Babesia caballi merozoite rhoptry protein and potential use of the recombinant antigen in an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 37:3475-3480.[Abstract/Free Full Text]
  8. Ikadai, H., C. R. Osorio, X. Xuan, I. Igarashi, H. Nagasawa, K. Fujisaki, N. Suzuki, and T. Mikami. 2000. Detection of Babesia caballi infection by enzyme-linked immunosorbent assay using recombinant 48-kDa merozoite rhoptry protein. Int. J. Parasitol. 30:633-635.[CrossRef][Medline]
  9. Knowles, D. P., Jr., L. E. Perryman, L. S. Kappmeyer, and S. G. Hennager. 1991. Detection of equine antibody to Babesia equi merozoite proteins by a monoclonal antibody-based competitive inhibition enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:2056-2058.[Abstract/Free Full Text]
  10. Tanaka, T., X. Xuan, H. Ikadai, I. Igarashi, H. Nagasawa, K. Fujisaki, T. Mikami, and N. Suzuki. 1999. Expression of Babesia equi merozoite antigen-2 by recombinant baculovirus and its use in the ELISA. Int. J. Parasitol. 29:1803-1808.[CrossRef][Medline]
  11. Tenter, A. M., and K. T. Friedhoff. 1986. Serodiagnosis of experimental and natural Babesia equi and B. caballi infections. Vet. Parasitol. 20:49-61.[CrossRef][Medline]
  12. Weiland, G. 1986. Species-specific serodiagnosis of equine piroplasma infections by means of complement fixation test, immunofluorescence, and enzyme-linked immunosorbent assay. Vet. Parasitol. 20:43-48.[CrossRef][Medline]
  13. Xuan, X., A. Larsen, H. Ikadai, T. Tanaka, I. Igarashi, H. Nagasawa, K. Fujisaki, Y. Toyoda, N. Suzuki, and T. Mikami. 2001. Expression of Babesia equi merozoite antigen 1 in insect cells by recombinant baculovirus and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 39:705-709.[Abstract/Free Full Text]
  14. Xuan, X., A. Nagai, B. Battsetseg, S. Fukumoto, L. H. Makala, N. Inoue, I. Igarashi, T. Mikami, and K. Fujisaki. 2001. Diagnosis of equine piroplasmosis in Brazil by serodiagnostic methods with recombinant antigens. J. Vet. Med. Sci. 63:1159-1160.[CrossRef][Medline]

Clinical and Vaccine Immunology, May 2006, p. 553-555, Vol. 13, No. 5
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.5.553-555.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.
Right arrow Articles by Igarashi, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.
Right arrow Articles by Igarashi, I.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS